In particular, its detection results corroborate and are supplementary to other well-known CSF biomarkers, such as p-tau181, which correlates well with amyloid/tau pathology [112], and p-tau217, which demonstrated a superior performance compared with p-tau181 in terms of sensitivity and specificity for AD [113,114]. This evidence concerns the gene MAPT and Alzheimer disease.